Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Liquidia CorpLQDA · Entity 1860 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Liquidia Corp
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 92,353 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 5,882 · Balance 92,353 F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 20:35 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock | 5,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-075788 · tm2618309-4_4seq1.xml · nonDerivative · entry 1 deGoa Damian · CIK 0001836165 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,353 F1 · kind: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · shares: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:30 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock | 18,396 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-061186 · tm2518541-2_4seq1.xml · nonDerivative · entry 1 deGoa Damian · CIK 0001836165 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,471 F1 · kind: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · shares: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. Read SEC document |
| June 20, 2024 Filed Jun 25, 2024 01:36 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock | 20,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-074469 · tm2418154-2_4seq1.xml · nonDerivative · entry 1 deGoa Damian · CIK 0001836165 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,075 F1 · kind: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · shares: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. Read SEC document |
| June 19, 2023 Filed Jun 21, 2023 21:03 UTC | Liquidia Corp LQDA · Entity 1860 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001104659-23-073397 · tm2317720-11_4seq1.xml · derivative · entry 1 deGoa Damian · CIK 0001836165 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-19 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on June 19, 2026. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:30 UTC | Liquidia Corp LQDA · Entity 1860 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001104659-22-073525 · tm2219055-1_4seq1.xml · derivative · entry 1 deGoa Damian · CIK 0001836165 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-17 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on June 17, 2025. Read SEC document |
| March 31, 2022 Filed Apr 20, 2022 20:36 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock | 4,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-047870 · tm2213052-3_4seq1.xml · nonDerivative · entry 1 deGoa Damian · CIK 0001836165 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,716 F1 · acquired: On March 31, 2022, 4,625 shares of the Issuer's common stock which were previously subject to a holdback pursuant to the terms of the merger agreement for Issuer's acquisition of RareGen, LLC ("RareGen") were released to the Reporting Person. The merger agreement provided that certain shares of the Issuer's common stock issuable to members of RareGen at the closing of the transaction would be held back as partial security for the benefit of the Issuer with respect to any indemnifiable damages pursuant to the indemnification obligations of the members of RareGen. The shares would subsequently be released for no additional consideration, subject to the cancellation of shares of the Issuer's common stock in connection with any such indemnifiable damages. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 22:11 UTC | Liquidia Corp LQDA · Entity 1860 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001104659-21-095507 · tm2123135-2_4seq1.xml · derivative · entry 1 deGoa Damian · CIK 0001836165 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-21 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on July 21, 2025; provided, however, that notwithstanding the foregoing vesting schedule, 50% of the shares of common sock underlying the option will vest upon U.S. Food and Drug Administration (FDA) tentative approval of the Issuer's New Drug Application for LIQ861. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 02:12 UTC | Liquidia Corp LQDA · Entity 1860 | GrantNonstatutory Stock Option (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001104659-20-135897 · tm2037368-4_4.xml · derivative · entry 1 deGoa Damian · CIK 0001836165 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2030-12-14 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on December 14, 2024; provided, however, that, notwithstanding the foregoing vesting schedule, (x) 25% of the shares of common stock underlying the option will vest upon U.S. Food and Drug Administration tentative approval of the issuer's New Drug Application for LIQ861 prior to June 30, 2022 and F2 · derivative.exercise_date: (y) 25% of the shares of common stock underlying the option will vest upon commercial availability of subcutaneous treprostinil with cartridge supplies sufficient to support the market for one year prior to December 31, 2021; provided, further, that upon a Change in Control (as defined in the accompanying Nonstatutory Stock Option Agreement) 100% of the unvested portion of the option shall become vested and exercisable as of the date of the Change in Control, provided that Mr. deGoa is actively employed with Liquidia Technologies, Inc. on such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.